- Tytuł:
- Fluorescence lifetime imaging ophthalmoscopy: autofluorescence imaging and beyond.
- Autorzy:
- Źródło:
- Eye (London, England) [Eye (Lond)] 2021 Jan; Vol. 35 (1), pp. 93-109. Date of Electronic Publication: 2020 Dec 02.
- Typ publikacji:
- Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
- Język:
- English
- Imprint Name(s):
-
Publication: <2003->: London : Nature Publishing Group
Original Publication: [London : Ophthalmological Society of the United Kingdom, 1987- - MeSH Terms:
-
Retinal Telangiectasis*
Tomography, Optical Coherence*
Fluorescein Angiography ; Humans ; Ophthalmoscopy ; Optical Imaging ; Retina/diagnostic imaging - References:
-
Lakowicz JR. Principles of fluorescence spectroscopy. New York: Springer; 2007.
Marcu L. Fluorescence lifetime techniques in medical applications. Ann Biomed Eng. 2012;40:304–31. (PMID: 22273730336895410.1007/s10439-011-0495-y)
Lakowicz JR, Szmacinski H, Nowaczyk K, Johnson ML. Fluorescence lifetime imaging of free and protein-bound NADH. Proc Natl Acad Sci USA. 1992;89:1271–5. (PMID: 174138010.1073/pnas.89.4.1271)
Schweitzer D, Kolb A, Hammer M, Anders R. Time-correlated measurement of autofluorescence. A method to detect metabolic changes in the fundus. Ophthalmologe. 2002;99:774–9. (PMID: 1237685310.1007/s00347-002-0656-3)
Schweitzer D, Schenke S, Hammer M, Schweitzer F, Jentsch S, Birckner E, et al. Towards metabolic mapping of the human retina. Microsc Res Tech. 2007;70:410–9. (PMID: 1739349610.1002/jemt.20427)
Becker W. The bh TCSPC handbook. 6th ed. Berlin: Becker & Hickl GmbH; 2014.
Sauer L, Schweitzer D, Ramm L, Augsten R, Hammer M, Peters S. Impact of macular pigment on fundus autofluorescence lifetimes. Investig Ophthalmol Vis Sci. 2015;56:4668–79. (PMID: 10.1167/iovs.14-15335)
ANSI. American National Standard for the Safe Use of Lasers. Orlando, FL: Laser Institute of America; 2000.
Delori FC, Webb RH, Sliney DH, American National Standards I. Maximum permissible exposures for ocular safety (ANSI 2000), with emphasis on ophthalmic devices. J Opt Soc Am A Opt Image Sci Vis. 2007;24:1250–65. (PMID: 1742947110.1364/JOSAA.24.001250)
Sauer L, Andersen KM, Li B, Gensure RH, Hammer M, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) of macular pigment. Investig Ophthalmol Vis Sci. 2018;59:3094–103. (PMID: 10.1167/iovs.18-23886)
Sauer L, Vitale AS, Milliken CM, Modersitzki NK, Blount D, Bernstein PS. Autofluorescence lifetimes measured with fluorescence lifetime imaging ophthalmoscopy (FLIO) are affected by age, but not by pigmentation or gender. Transl Vis Sci Technol. 2020;9:2. (PMID: 32879759744288010.1167/tvst.9.9.2)
Klemm M, Dietzel A, Haueisen J, Nagel E, Hammer M, Schweitzer D. Repeatability of autofluorescence lifetime imaging at the human fundus in healthy volunteers. Curr Eye Res. 2013;38:793–801. (PMID: 2353099510.3109/02713683.2013.779723)
Dysli C, Quellec G, Abegg M, Menke MN, Wolf-Schnurrbusch U, Kowal J, et al. Quantitative analysis of fluorescence lifetime measurements of the macula using the fluorescence lifetime imaging ophthalmoscope in healthy subjects. Investig Ophthalmol Vis Sci. 2014;55:2106–13. (PMID: 10.1167/iovs.13-13627)
Kwon S, Borrelli E, Fan W, Ebraheem A, Marion KM, Sadda SR. Repeatability of fluorescence lifetime imaging ophthalmoscopy in normal subjects with mydriasis. Transl Vis Sci Technol. 2019;8:15. (PMID: 31114715650620310.1167/tvst.8.3.15)
Klemm M, Sauer L, Klee S, Link D, Peters S, Hammer M, et al. Bleaching effects and fluorescence lifetime imaging ophthalmoscopy. Biomed Opt Express. 2019;10:1446–61. (PMID: 30891358642030110.1364/BOE.10.001446)
Hammer M, Konigsdorffer E, Liebermann C, Framme C, Schuch G, Schweitzer D, et al. Ocular fundus auto-fluorescence observations at different wavelengths in patients with age-related macular degeneration and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:105–14. (PMID: 1765375210.1007/s00417-007-0639-9)
Sauer L, Peters S, Schmidt J, Schweitzer D, Klemm M, Ramm L, et al. Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy. Acta Ophthalmol. 2017;95:481–92. (PMID: 2777522210.1111/aos.13269)
Ermakov IV, McClane RW, Gellermann W, Bernstein PS. Resonant Raman detection of macular pigment levels in the living human retina. Opt Lett. 2001;26:202–4. (PMID: 1803354710.1364/OL.26.000202)
Jaggi DSY, Dysli C, Wolf S, Zinkernagel M. Fluorescence lifetime imaging ophthalmoscopy and the influence of oral lutein supplementation on macular pigment: a preliminary study report. Paris: EURetina; 2019.
Greenberg JP, Duncker T, Woods RL, Smith RT, Sparrow JR, Delori FC. Quantitative fundus autofluorescence in healthy eyes. Investig Ophthalmol Vis Sci. 2013;54:5684–93. (PMID: 10.1167/iovs.13-12445)
Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72. (PMID: 1507867510.1001/archopht.122.7.1019)
Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38:450–71. (PMID: 17101537485395710.1080/07853890600946724)
Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128:750–8. (PMID: 20547953289621710.1001/archophthalmol.2010.92)
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51. (PMID: 2333259010.1016/j.ophtha.2012.10.036)
Age-Related Eye Disease Study 2 Research Group, Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142–9. (PMID: 10.1001/jamaophthalmol.2013.7376)
Sauer L, Gensure RH, Andersen KM, Kreilkamp L, Hageman GS, Hammer M, et al. Patterns of fundus autofluorescence lifetimes in eyes of individuals with nonexudative age-related macular degeneration. Investig Ophthalmol Vis Sci. 2018;59:AMD65–77. (PMID: 10.1167/iovs.17-23764)
Dysli C, Fink R, Wolf S, Zinkernagel MS. Fluorescence lifetimes of drusen in age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58:4856–62. (PMID: 10.1167/iovs.17-22184)
Dysli C, Wolf S, Zinkernagel MS. Autofluorescence lifetimes in geographic atrophy in patients with age-related macular degeneration. Investig Ophthalmol Vis Sci. 2016;57:2479–87. (PMID: 10.1167/iovs.15-18381)
Sauer L, Klemm M, Peters S, Schweitzer D, Schmidt J, Kreilkamp L, et al. Monitoring foveal sparing in geographic atrophy with fluorescence lifetime imaging ophthalmoscopy—a novel approach. Acta Ophthalmol. 2018;96:257–66. (PMID: 2910536210.1111/aos.13587)
Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis. 1999;5:28. (PMID: 10562652)
Pepple K, Mruthyunjaya P. Retinal pigment epithelial detachments in age-related macular degeneration: classification and therapeutic options. Semin Ophthalmol. 2011;26:198–208. (PMID: 2160923310.3109/08820538.2011.570850)
Sauer L, Komanski CB, Vitale AS, Hansen ED, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) in eyes with pigment epithelial detachments due to age-related macular degeneration. Investig Ophthalmol Vis Sci. 2019;60:3054–63. (PMID: 10.1167/iovs.19-26835)
Schweitzer D, Gaillard ER, Dillon J, Mullins RF, Russell S, Hoffmann B, et al. Time-resolved autofluorescence imaging of human donor retina tissue from donors with significant extramacular drusen. Investig Ophthalmol Vis Sci. 2012;53:3376–86. (PMID: 10.1167/iovs.11-8970)
Schweitzer D, Quick S, Schenke S, Klemm M, Gehlert S, Hammer M, et al. Comparison of parameters of time-resolved autofluorescence between healthy subjects and patients suffering from early AMD. Ophthalmologe. 2009;106:714–22. (PMID: 1958815610.1007/s00347-009-1975-4)
Eisma JH, Dulle JE, Fort PE. Current knowledge on diabetic retinopathy from human donor tissues. World J Diabetes. 2015;6:312–20. (PMID: 25789112436042410.4239/wjd.v6.i2.312)
Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–80. (PMID: 2593664910.1016/j.preteyeres.2015.04.003)
Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27. (PMID: 24955234404614210.1186/2045-3701-4-27)
Guerin-Dubourg A, Cournot M, Planesse C, Debussche X, Meilhac O, Rondeau P, et al. Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. Biomed Res Int. 2017;2017:7989180. (PMID: 29362717573694510.1155/2017/7989180)
Schmidt J, Peters S, Sauer L, Schweitzer D, Klemm M, Augsten R, et al. Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy. Acta Ophthalmol. 2017;95:33–40. (PMID: 2751981510.1111/aos.13174)
Schweitzer D, Deutsch L, Klemm M, Jentsch S, Hammer M, Peters S, et al. Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy. J Biomed Opt. 2015;20:61106. (PMID: 2576927810.1117/1.JBO.20.6.061106)
Schweitzer D. Metabolic mapping. In: Holz F, Spaide R, editors. Medical retina. Essentials in ophthalmology. Berlin: Springer Berlin Heidelberg; 2010. p. 107–23.
Schweitzer D, Quick S, Klemm M, Hammer M, Jentsch S, Dawczynski J. Time-resolved autofluorescence in retinal vascular occlusions. Ophthalmologe. 2010;107:1145–52. (PMID: 2055236110.1007/s00347-010-2195-7)
Hammer M, Sauer L, Klemm M, Peters S, Schultz R, Haueisen J. Fundus autofluorescence beyond lipofuscin: lesson learned from ex vivo fluorescence lifetime imaging in porcine eyes. Biomed Opt Express. 2018;9:3078–91. (PMID: 29984084603358310.1364/BOE.9.003078)
Abulrob A, Brunette E, Slinn J, Baumann E, Stanimirovic D. Dynamic analysis of the blood-brain barrier disruption in experimental stroke using time domain in vivo fluorescence imaging. Mol Imaging. 2008;7:7290.2008.00025. (PMID: 10.2310/7290.2008.00025)
Hamasaki DI, Kroll AJ. Experimental central retinal artery occlusion: an electrophysiological study. Arch Ophthalmol. 1968;80:243–8. (PMID: 496941910.1001/archopht.1968.00980050245019)
Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, et al. Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol. 2019;13:2341–52. (PMID: 31819359689706710.2147/OPTH.S220845)
Iyer PG, Schwartz SG, Russell JF, Flynn HW. Central serous chorioretinopathy: multimodal imaging and management options. Case Rep Ophthalmol. 2020;2020:8890404.
Dysli C, Berger L, Wolf S, Zinkernagel MS. Fundus autofluorescence lifetimes and central serous chorioretinopathy. Retina. 2017;37:2151–61. (PMID: 28099314569030210.1097/IAE.0000000000001452)
Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77. (PMID: 2321969210.1016/j.preteyeres.2012.11.002)
Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159:659–66 e1. (PMID: 2552895610.1016/j.ajo.2014.12.013)
Gantner ML, Eade K, Wallace M, Handzlik MK, Fallon R, Trombley J, et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N Engl J Med. 2019;381:1422–33. (PMID: 31509666768548810.1056/NEJMoa1815111)
Sauer L, Gensure RH, Hammer M, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy: a novel way to assess macular telangiectasia type 2. Ophthalmol Retina 2018;2:587–98. (PMID: 3011679610.1016/j.oret.2017.10.008)
Sauer L, Vitale AS, Andersen KM, Hart B, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) patterns in clinically unaffected children of macular telangiectasia type 2 (MacTel) patients. Retina. 2020;40:695–704. (PMID: 3151772710.1097/IAE.0000000000002646)
Solberg Y, Dysli C, Wolf S, Zinkernagel MS. Fluorescence lifetime patterns in macular telangiectasia type 2. Retina. 2020;40:99–108. (PMID: 3066412310.1097/IAE.0000000000002411)
Michaelides M, Hunt DM, Moore AT. The genetics of inherited macular dystrophies. J Med Genet. 2003;40:641–50. (PMID: 12960208173557610.1136/jmg.40.9.641)
Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology. 2017;124:1314–31. (PMID: 28559085556570410.1016/j.ophtha.2017.04.008)
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15:236–46. (PMID: 905493410.1038/ng0397-236)
Boyer NP, Higbee D, Currin MB, Blakeley LR, Chen C, Ablonczy Z, et al. Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem. 2012;287:22276–86. (PMID: 22570475338118810.1074/jbc.M111.329235)
Zhang N, Tsybovsky Y, Kolesnikov AV, Rozanowska M, Swider M, Schwartz SB, et al. Protein misfolding and the pathogenesis of ABCA4-associated retinal degenerations. Hum Mol Genet. 2015;24:3220–37. (PMID: 25712131442495710.1093/hmg/ddv073)
Cideciyan AV, Aleman TS, Swider M, Schwartz SB, Steinberg JD, Brucker AJ, et al. Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet. 2004;13:525–34. (PMID: 1470959710.1093/hmg/ddh048)
Dysli C, Wolf S, Hatz K, Zinkernagel MS. Fluorescence lifetime imaging in Stargardt disease: potential marker for disease progression. Investig Ophthalmol Vis Sci. 2016;57:832–41. (PMID: 10.1167/iovs.15-18033)
Solberg Y, Dysli C, Escher P, Berger L, Wolf S, Zinkernagel MS. Retinal flecks in Stargardt disease reveal characteristic fluorescence lifetime transition over time. Retina. 2019;39:879–88. (PMID: 30985551651032210.1097/IAE.0000000000002519)
Ablonczy Z, Gutierrez DB, Grey AC, Schey KL, Crouch RK. Molecule-specific imaging and quantitation of A2E in the RPE. Adv Exp Med Biol. 2012;723:75–81. (PMID: 2218331810.1007/978-1-4614-0631-0_11)
Sears AE, Bernstein PS, Cideciyan AV, Hoyng C, Charbel Issa P, Palczewski K, et al. Towards treatment of Stargardt disease: workshop organized and sponsored by the foundation fighting blindness. Transl Vis Sci Technol. 2017;6:6. (PMID: 28920007559922810.1167/tvst.6.5.6)
Mitsios A, Dubis AM, Moosajee M. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol. 2018;10:2515841418817490. (PMID: 306276976311551)
Vitale AS, Sauer L, Modersitzki NK, Bernstein PS. Fluorescence lifetime imaging ophthalmoscopy (FLIO) in patients with choroideremia. Transl Vis Sci Technol 2020;9:33. (PMID: 33062396753373710.1167/tvst.9.10.33)
Pagon RA. Retinitis pigmentosa. Surv Ophthalmol. 1988;33:137–77. (PMID: 306882010.1016/0039-6257(88)90085-9)
Dysli C, Schurch K, Pascal E, Wolf S, Zinkernagel MS. Fundus autofluorescence lifetime patterns in retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2018;59:1769–78. (PMID: 10.1167/iovs.17-23336)
Andersen KM, Sauer L, Gensure RH, Hammer M, Bernstein PS. Characterization of retinitis pigmentosa using fluorescence lifetime imaging ophthalmoscopy (FLIO). Transl Vis Sci Technol. 2018;7:20. (PMID: 29946494601650710.1167/tvst.7.3.20)
Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic vitreomacular adhesion. Retina. 2013;33:1503–11. (PMID: 2371485710.1097/IAE.0b013e31829232fd)
Jaggi D, Solberg Y, Dysli C, Ebneter A, Wolf S, Zinkernagel MS. Fluorescence lifetime imaging ophthalmoscopy: findings after surgical reattachment of macula-off rhegmatogenous retinal detachment. Retina. 2020;40:1929–37. (PMID: 31860523)
Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771–9. (PMID: 2757893137980410.1111/j.1365-2125.1989.tb03439.x)
de Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Investig Ophthalmol Vis Sci. 2015;56:3415–26. (PMID: 10.1167/iovs.14-16345)
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF.American Academy of Ophthalmology Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123:1386–94. (PMID: 2699283810.1016/j.ophtha.2016.01.058)
Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14:693–703. (PMID: 3040197910.1038/s41584-018-0111-8)
Sauer LC, Calvo CM, Vitale, AS, Henrie, N, Milliken, CM, Bernstein, PS. Imaging of hydroxychloroquine toxicity with fluorescence lifetime imaging ophthalmoscopy (FLIO). Ophthalmol Retina. 2019;3:814–25. (PMID: 3134572710.1016/j.oret.2019.04.025)
Solberg Y, Dysli C, Moller B, Wolf S, Zinkernagel MS. Fluorescence lifetimes in patients with hydroxychloroquine retinopathy. Investig Ophthalmol Vis Sci. 2019;60:2165–72. (PMID: 10.1167/iovs.18-26079)
Gakamsky A, Duncan RR, Howarth NM, Dhillon B, ButtenschN KK, Daly DJ, et al. Tryptophan and non-tryptophan fluorescence of the eye lens proteins provides diagnostics of cataract at the molecular level. Sci Rep. 2017;7:40375. (PMID: 28071717522318110.1038/srep40375)
Brauer JL, Schultz R, Klemm M, Hammer M. Influence of lens fluorescence on fluorescence lifetime imaging ophthalmoscopy (FLIO) fundus imaging and strategies for its compensation. Transl Vis Sci Technol. 2020;9:13. (PMID: 32855860742275610.1167/tvst.9.8.13)
Klemm M, Blum J, Link D, Hammer M, Haueisen J, Schweitzer D. Combination of confocal principle and aperture stop separation improves suppression of crystalline lens fluorescence in an eye model. Biomed Opt Express. 2016;7:3198–210. (PMID: 27699092503000410.1364/BOE.7.003198)
Schweitzer D, Hammer M, Schweitzer F. Limits of the confocal laser-scanning technique in measurements of time-resolved autofluorescence of the ocular fundus. Biomed Tech. 2005;50:263–7. (PMID: 10.1515/BMT.2005.038)
Ramm L, Jentsch S, Augsten R, Hammer M. Fluorescence lifetime imaging ophthalmoscopy in glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2014;252:2025–6. (PMID: 10.1007/s00417-014-2813-1)
Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018;7:F1000 Faculty Rev-1161.
Bambo MP, Garcia-Martin E, Pinilla J, Herrero R, Satue M, Otin S, et al. Detection of retinal nerve fiber layer degeneration in patients with Alzheimer’s disease using optical coherence tomography: searching new biomarkers. Acta Ophthalmol. 2014;92:e581–2. (PMID: 2459293510.1111/aos.12374)
Javaid FZ, Brenton J, Guo L, Cordeiro MF. Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression. Front Neurol. 2016;7:55. (PMID: 27148157483613810.3389/fneur.2016.00055)
Jentsch S, Schweitzer D, Schmidtke KU, Peters S, Dawczynski J, Bär KJ, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol. 2015;93:e241–7. (PMID: 2548299010.1111/aos.12609)
Kwon S, Fang W, Borreli E, Ebraheem A, Marion K, Katayama Y, et al. Fluorescence lifetime imaging ophthalmoscopy in early Alzheimer’s disease. Honolulu, Hawaii, USA: ARVO Annual Meeting; 2018. - Grant Information:
- P30 EY014800 United States EY NEI NIH HHS; R01 EY011600 United States EY NEI NIH HHS; R29 EY011600 United States EY NEI NIH HHS
- Contributed Indexing:
- Local Abstract: [Publisher, Chinese] 摘要: 近年来, 荧光活体实时成像检眼镜(FLIO)在科学界引起了广泛的兴趣。它是一种非侵入性的成像方式, 已被证明可以为其他常规成像方式提供更多额外的信息。FLIO装置基于海德堡的spectralis系统。FLIO的激发波长为473 nm, 并记录在两个光谱波长的通道中, 一个是短光谱通道(SSC, 498–560 nm), 另一个是长光谱通道(LSC, 560–720 nm)。一般用于研究30度视网膜范围的自体荧光。FLIO在不同视网膜疾病中成像优势明显。例如, 在与年龄相关的黄斑变性(AMD)中, 可以观察到距中央凹1.5 mm至3.0 mm的FLIO活体的环形图案;在2型黄斑毛细血管扩张(MacTel)中可观察到不同类型影像, 但FLIO影像在MacTel区域的不同表现;在Stargardt病中, 视网膜斑点可以在其他成像方式检测之前就可被识别出来;早期的羟氯喹视网膜病变也可以用FLIO进行识别。因此这项技术还有更多有待开发的潜力。这篇综述重点介绍了该技术的现状和缺陷。强调了FLIO成像在不同眼科和全身性疾病中的临床优势, 并且提出了对于该技术的展望。.
- Entry Date(s):
- Date Created: 20201203 Date Completed: 20210618 Latest Revision: 20240214
- Update Code:
- 20240214
- PubMed Central ID:
- PMC7852552
- DOI:
- 10.1038/s41433-020-01287-y
- PMID:
- 33268846
- Czasopismo naukowe
Menu główne
Wyszukiwarka
Treść główna
